Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics’ EsoCheck and EsoGuard Technologies
24 mai 2021 09h30 HE
|
PAVmed Inc.
Initial NYU experience in 99 patients demonstrated EsoCheck and EsoGuard capable of detecting esophageal precancer in chronic heartburn patients NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) --...